Safety of Tetravalent Conjugate Meningococcal Vaccine (Serotypes A, C, Y, W) for 1–4 Years Old Children With Distresses and Chronic Diseases in Closed Healthcare Facility: Cohort Study

Background. Tolerance to immunization with conjugate tetravalent vaccine against meningococcal infection (serotypes A, C, Y, W) for vulnerable categories of children has not been studied before.

The aim of the study is to estimate the safety of the conjugate tetravalent vaccine against meningococcal disease serotypes A, C, Y, W in children who deprived of parental care. 

Methods. Our cohort prospective study included 1-4 years old children with distresses and chronic diseases (neurological disorders, congenital defects, genetic diseases, allergy) in closed healthcare facility. The safety of tetravalent conjugate meningococcal vaccine (serotypes A, C, Y, W) was measured in 24-hour hospital during 7 days after vaccination in two ways: mono-vaccination and combined vaccination (with other vaccines from National vaccination calendar). General and local adverse effects (AE) were registered. 

Results. 105 children were immunized. 94 children (89.5 %) had asymptomatic postvaccinal period after using monoand co-vaccination. General AEs such as fever, long-lasting crying, vomiting, diarrhea and drowsiness were not registered at all. Local AEs such as pain, hyperemia and edema in injection site were registered in 11 (10,5 %) children. All local AEs were mild and recovered fast both in mono-vaccination and combined vaccination. No aggravations of primary disease were mentioned. 

Conclusion. We can notice good immunization’s tolerance in children with diseases and parental deprevation using the conjugate tetravalent vaccination against meningococcal disease (serotypes A, C, Y, W) in mono-vaccination and combined vaccination.

1. Meningokokkovaya infektsiya i gnoynyye bakterial’nyye meningity v RF v 2017 g. Informatsionno-analiticheskiy obzor rossiyskogo referens-tsentra po monitoringu za MI i GBM Federal’noy sluzhby Rospotrebnadzora RF [Internet]. Moscow; 2018. (In Russ).

2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27 Suppl 2:B51–63. doi: 10.1016/j.vaccine.2009.04.063.

3. State report “O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2017 godu”[Internet]. Moscow: The Federal Service; 2018. (In Russ). Available from: https://rospotrebnadzor.ru/upload/iblock/d9d/gd_2017_seb.pdf. Access date: 16.02.2019.

4. Polibin RV, Mindlina AYa, Gerasimov AA, Briko NI. Comparative analysis of mortality from infectious diseases in the Russian Federation and some European countries. Epidemiologiya i vaktsinoprofilaktika. 2017;16(3):4–10. (In Russ).

5. State report “O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2018 godu” [Internet]. Moscow: The Federal Service; 2019. (In Russ). Available from: https://rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=12053. Access date: 16.02.2019.

6. Ivanova MV, Skripchenko NV, Vil’nits AA, et al. The course of generalized meningococcal infection caused by meningococcus serogroup W135. Detskiye infektsii. 2016;15(4):57–60. (In Russ).

7. Martinon-Torres F. Deciphering the burden of meningococcal disease: conventional and under-recognized elements. J Adolesc Health. 2016;59(2 Suppl):S12–20. doi: 10.1016/j.jadohealth.2016.03.041.

8. Bedford H, de Louvois J, Halket S, et al. Meningitis in infancy in England and Wales: Follow up at age 5 years. BMJ. 2001;323(7312):533–536. doi: 10.1136/bmj.323.7312.533.

9. Tatochenko VK, Ozeretskovskiy NA. Immunoprofilaktika-2018. 13th. Moscow: Pediatr”; 2018. Р. 137. (In Russ).

10. Mazankova LN, Guseva GD, Soldatova IA. Epidemiological and clinical features of bacterial purulent meningitis in children of Moscow. Detskiye infektsii. 2018;17(1):5–11. (In Russ). doi: 10.22627/2072-8107-2018-171-5-11.

11. Resolution of the Chief state sanitary doctor of the Russian Federation No. 52 «Ob utverzhdenii sanitarnoepidemiologicheskikh pravil SP 3.1.3542-18 “Profilaktika meningokokkovoy infektsii”; dated 2018 December 20. (In Russ). Available from: https://www.garant.ru/products/ipo/prime/doc/72043808/. Access date: 16.02.2019.

12. Soyuz pediatrov Rossii. Immunoprofilaktika meningokokkovoy infektsii u detey. Metodicheskiye rekomendatsii. 2nd revised and updated. Moscow: Pediatr”; 2019. 36 р. (In Russ).

13. Namazova-Baranova LS, Novikova DA, Fedoseenko MV, et al. Safety of combination of a tetravalent meningococcal conjugate vaccine against serogroups A, C, Y, W-135 with other vaccine preparations: a prospective study of a series of cases among healthy children and children with various health abnormalities. Current Pediatrics. 2017;16(2):156–162. (In Russ). doi: 10.15690/vsp.v16i2.1717.

14. Solonina OV, Sy TM. The safety of 4-valent meningococcal conjugate vaccine in two years old children: prospective cohort study in Sakhalin Region. Current Pediatrics. 2019;18(3):175–179. (In Russ). doi: 10.15690/vsp.v18i3.2034.